This review article examined nicotinamide mononucleotide (NMN) as a potential anti-aging intervention, evaluating both its proposed benefits and safety profile across available evidence. The authors identified promises in preclinical models and limited human data regarding metabolic and cardiovascular effects, while also highlighting gaps in long-term safety data and regulatory oversight for NMN as a commercial health product. This is a **review article** synthesizing existing literature rather than original human clinical research.